Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2018 Feb 15;45(8):1372–1381. doi: 10.1007/s00259-018-3941-3

Figure 4.

Figure 4

Biodistribution results at 120 h p.i. of 89Zr-Df-daratumumab or 89Zr-Df-IgG. Ramos tumors showed significantly higher uptake than HBL-1 tumors and nonspecific IgG group, which verified the results from PET imaging. Both radiolabeled daratumumab and IgG showed relatively high uptake in blood and blood-rich organs, such as lungs, spleen. **p < 0.01; n = 4.